Which has higher valuation and earnings, BBIO or ARGX?

argenex has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BridgeBio Pharma $502.08M 31.73 -$724.93M -$3.57 N/A argenex $4.25B 15.31 $1.29B $26.04 39.93

Does the media favor BBIO or ARGX?

In the previous week, argenex had 36 more articles in the media than BridgeBio Pharma. MarketBeat recorded 42 mentions for argenex and 6 mentions for BridgeBio Pharma. argenex's average media sentiment score of 0.75 beat BridgeBio Pharma's score of 0.48 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral argenex 13 Very Positive mention(s) 9 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, BBIO or NTRA?

Natera has higher revenue and earnings than BridgeBio Pharma. Natera is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BridgeBio Pharma $502.08M 31.73 -$724.93M -$3.57 N/A Natera $2.31B 20.75 -$208.16M -$1.36 N/A

Does the media favor BBIO or NTRA?

In the previous week, Natera had 24 more articles in the media than BridgeBio Pharma. MarketBeat recorded 30 mentions for Natera and 6 mentions for BridgeBio Pharma. Natera's average media sentiment score of 1.34 beat BridgeBio Pharma's score of 0.48 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Natera 25 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BBIO or RVMD?

In the previous week, Revolution Medicines had 6 more articles in the media than BridgeBio Pharma. MarketBeat recorded 12 mentions for Revolution Medicines and 6 mentions for BridgeBio Pharma. Revolution Medicines' average media sentiment score of 1.31 beat BridgeBio Pharma's score of 0.48 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Revolution Medicines 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger earnings and valuation, BIIB or BBIO?

Biogen has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $10.03B 3.19 $1.29B $5.65 38.37 BridgeBio Pharma $502.08M 31.73 -$724.93M -$3.57 N/A

Does the media refer more to BIIB or BBIO?

In the previous week, Biogen had 22 more articles in the media than BridgeBio Pharma. MarketBeat recorded 28 mentions for Biogen and 6 mentions for BridgeBio Pharma. Biogen's average media sentiment score of 1.35 beat BridgeBio Pharma's score of 0.48 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 22 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ALNY or BBIO?

In the previous week, Alnylam Pharmaceuticals had 19 more articles in the media than BridgeBio Pharma. MarketBeat recorded 25 mentions for Alnylam Pharmaceuticals and 6 mentions for BridgeBio Pharma. Alnylam Pharmaceuticals' average media sentiment score of 0.81 beat BridgeBio Pharma's score of 0.48 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

BridgeBio Pharma (BBIO) Competitors

$81.50 -1.44 (-1.74%)

As of 08/21/2026 04:00 PM Eastern

Compare

BBIO vs. ARGX, NTRA, RVMD, BIIB, and ALNY

Should you buy BridgeBio Pharma stock or one of its competitors? BridgeBio Pharma's main competitors and comparable companies include argenex (ARGX), Natera (NTRA), Revolution Medicines (RVMD), Biogen (BIIB), and Alnylam Pharmaceuticals (ALNY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BridgeBio Pharma compare to argenex?

BridgeBio Pharma (NASDAQ:BBIO) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

argenex has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	31.73	-$724.93M	-$3.57	N/A
argenex	$4.25B	15.31	$1.29B	$26.04	39.93

argenex has a net margin of 32.19% compared to BridgeBio Pharma's net margin of -97.03%. argenex's return on equity of 43.59% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
argenex	32.19%	43.59%	36.66%

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 2.4% of argenex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BridgeBio Pharma currently has a consensus price target of $100.79, indicating a potential upside of 23.67%. argenex has a consensus price target of $1,118.28, indicating a potential upside of 7.55%. Given BridgeBio Pharma's higher probable upside, equities analysts plainly believe BridgeBio Pharma is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

In the previous week, argenex had 36 more articles in the media than BridgeBio Pharma. MarketBeat recorded 42 mentions for argenex and 6 mentions for BridgeBio Pharma. argenex's average media sentiment score of 0.75 beat BridgeBio Pharma's score of 0.48 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
argenex	13 Very Positive mention(s)	9 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, argenex has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

Summary

argenex beats BridgeBio Pharma on 11 of the 17 factors compared between the two stocks.

How does BridgeBio Pharma compare to Natera?

BridgeBio Pharma (NASDAQ:BBIO) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, Natera had 24 more articles in the media than BridgeBio Pharma. MarketBeat recorded 30 mentions for Natera and 6 mentions for BridgeBio Pharma. Natera's average media sentiment score of 1.34 beat BridgeBio Pharma's score of 0.48 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Natera	25 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 5.1% of Natera shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BridgeBio Pharma has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Natera has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market.

Natera has higher revenue and earnings than BridgeBio Pharma. Natera is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	31.73	-$724.93M	-$3.57	N/A
Natera	$2.31B	20.75	-$208.16M	-$1.36	N/A

BridgeBio Pharma currently has a consensus price target of $100.79, suggesting a potential upside of 23.67%. Natera has a consensus price target of $319.38, suggesting a potential downside of 3.81%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe BridgeBio Pharma is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

Natera has a net margin of -7.11% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Natera	-7.11%	-11.38%	-7.87%

Summary

Natera beats BridgeBio Pharma on 10 of the 17 factors compared between the two stocks.

How does BridgeBio Pharma compare to Revolution Medicines?

BridgeBio Pharma (NASDAQ:BBIO) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

BridgeBio Pharma presently has a consensus target price of $100.79, suggesting a potential upside of 23.67%. Revolution Medicines has a consensus target price of $167.89, suggesting a potential downside of 19.85%. Given BridgeBio Pharma's higher probable upside, research analysts clearly believe BridgeBio Pharma is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

BridgeBio Pharma has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	31.73	-$724.93M	-$3.57	N/A
Revolution Medicines	$11.58M	3,877.00	-$1.13B	-$8.82	N/A

BridgeBio Pharma has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

Revolution Medicines has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Revolution Medicines	N/A	-88.20%	-57.85%

In the previous week, Revolution Medicines had 6 more articles in the media than BridgeBio Pharma. MarketBeat recorded 12 mentions for Revolution Medicines and 6 mentions for BridgeBio Pharma. Revolution Medicines' average media sentiment score of 1.31 beat BridgeBio Pharma's score of 0.48 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

BridgeBio Pharma beats Revolution Medicines on 9 of the 17 factors compared between the two stocks.

How does BridgeBio Pharma compare to Biogen?

Biogen (NASDAQ:BIIB) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

87.9% of Biogen shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 0.3% of Biogen shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Biogen has a net margin of 8.32% compared to BridgeBio Pharma's net margin of -97.03%. Biogen's return on equity of 11.18% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
BridgeBio Pharma	-97.03%	N/A	-61.19%

In the previous week, Biogen had 22 more articles in the media than BridgeBio Pharma. MarketBeat recorded 28 mentions for Biogen and 6 mentions for BridgeBio Pharma. Biogen's average media sentiment score of 1.35 beat BridgeBio Pharma's score of 0.48 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	22 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biogen has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

Biogen has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$10.03B	3.19	$1.29B	$5.65	38.37
BridgeBio Pharma	$502.08M	31.73	-$724.93M	-$3.57	N/A

Biogen currently has a consensus target price of $227.07, suggesting a potential upside of 4.75%. BridgeBio Pharma has a consensus target price of $100.79, suggesting a potential upside of 23.67%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Biogen beats BridgeBio Pharma on 10 of the 17 factors compared between the two stocks.

How does BridgeBio Pharma compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

In the previous week, Alnylam Pharmaceuticals had 19 more articles in the media than BridgeBio Pharma. MarketBeat recorded 25 mentions for Alnylam Pharmaceuticals and 6 mentions for BridgeBio Pharma. Alnylam Pharmaceuticals' average media sentiment score of 0.81 beat BridgeBio Pharma's score of 0.48 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alnylam Pharmaceuticals presently has a consensus price target of $386.62, indicating a potential upside of 63.67%. BridgeBio Pharma has a consensus price target of $100.79, indicating a potential upside of 23.67%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Alnylam Pharmaceuticals is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.96
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Alnylam Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$4.80B	6.58	$313.75M	$5.38	43.91
BridgeBio Pharma	$502.08M	31.73	-$724.93M	-$3.57	N/A

Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to BridgeBio Pharma's net margin of -97.03%. Alnylam Pharmaceuticals' return on equity of 84.93% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
BridgeBio Pharma	-97.03%	N/A	-61.19%

Summary

Alnylam Pharmaceuticals beats BridgeBio Pharma on 12 of the 17 factors compared between the two stocks.

Get BridgeBio Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBIO vs. The Competition

Export

Metric	BridgeBio Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.93B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-22.83	11.62	272.60	24.25
Price / Sales	31.73	1,334.62	624.33	101.47
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	-6.36	16.80	13.05	6.20
Net Income	-$724.93M	-$12.50M	$3.47B	$348.59M
7 Day Performance	2.05%	3.29%	2.09%	0.08%
1 Month Performance	-1.72%	8.23%	6.64%	3.88%
1 Year Performance	66.06%	55.05%	25.02%	16.98%

BridgeBio Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBIO BridgeBio Pharma	3.2645 of 5 stars	$81.50 -1.7%	$100.79 +23.7%	+66.1%	$15.93B	$502.08M	N/A	400	Insider Trade
ARGX argenex	4.2608 of 5 stars	$866.11 +0.1%	$1,056.89 +22.0%	+57.5%	$54.12B	$4.25B	33.26	1,863	Trending News Analyst Forecast Analyst Revision
NTRA Natera	2.5749 of 5 stars	$318.35 -1.2%	$301.90 -5.2%	+100.5%	$46.13B	$2.31B	N/A	6,140	News Coverage Positive News
RVMD Revolution Medicines	2.5234 of 5 stars	$206.97 +0.9%	$160.68 -22.4%	+466.0%	$43.97B	$11.58M	N/A	250	Analyst Forecast
BIIB Biogen	3.9582 of 5 stars	$207.13 -0.4%	$224.61 +8.4%	+55.6%	$30.72B	$10.03B	36.66	7,500	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBIO) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BridgeBio Pharma (BBIO) Competitors

BBIO vs. ARGX, NTRA, RVMD, BIIB, and ALNY

How does BridgeBio Pharma compare to argenex?

Summary

How does BridgeBio Pharma compare to Natera?

Summary

How does BridgeBio Pharma compare to Revolution Medicines?

Summary

How does BridgeBio Pharma compare to Biogen?

Summary

How does BridgeBio Pharma compare to Alnylam Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBIO vs. The Competition

BridgeBio Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BridgeBio Pharma (BBIO) Competitors

BBIO vs. ARGX, NTRA, RVMD, BIIB, and ALNY

How does BridgeBio Pharma compare to argenex?

Which has higher valuation and earnings, BBIO or ARGX?

Is BBIO or ARGX more profitable?

Do insiders & institutionals have more ownership in BBIO or ARGX?

Do analysts recommend BBIO or ARGX?

Does the media favor BBIO or ARGX?

Which has more volatility and risk, BBIO or ARGX?

Summary

How does BridgeBio Pharma compare to Natera?

Does the media favor BBIO or NTRA?

Do insiders and institutionals hold more shares of BBIO or NTRA?

Which has more volatility & risk, BBIO or NTRA?

Which has stronger earnings and valuation, BBIO or NTRA?

Do analysts recommend BBIO or NTRA?

Is BBIO or NTRA more profitable?

Summary

How does BridgeBio Pharma compare to Revolution Medicines?

Do analysts recommend BBIO or RVMD?

Which has better earnings & valuation, BBIO or RVMD?

Which has more risk and volatility, BBIO or RVMD?

Is BBIO or RVMD more profitable?

Does the media refer more to BBIO or RVMD?

Do insiders & institutionals hold more shares of BBIO or RVMD?

Summary

How does BridgeBio Pharma compare to Biogen?

Do institutionals & insiders believe in BIIB or BBIO?

Is BIIB or BBIO more profitable?

Does the media refer more to BIIB or BBIO?

Which has more volatility & risk, BIIB or BBIO?

Which has stronger earnings and valuation, BIIB or BBIO?

Do analysts prefer BIIB or BBIO?

Summary

How does BridgeBio Pharma compare to Alnylam Pharmaceuticals?

Does the media refer more to ALNY or BBIO?

Do analysts prefer ALNY or BBIO?

Which has better valuation and earnings, ALNY or BBIO?

Which has more risk and volatility, ALNY or BBIO?

Do insiders & institutionals believe in ALNY or BBIO?

Is ALNY or BBIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBIO vs. The Competition

BridgeBio Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools